Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Noninfectious Uveitis

Noninfectious Uveitis EDITORIAL A Scarcity of Randomized Clinical Trials UTOIMMUNE DISEASES ARE MAKING THE years found a significant increase in serum creatinine lev- headlines these days, with the reporting els and a significant decrease in creatinine clearance and of results from clinical trial after clinical glomerular filtration rate. All renal effects were dose- trial of various new treatments. Not sur- dependent. Eleven of the patients who underwent renal A prisingly, such clinical trials have all been biopsy prior to and after 2 years of cyclosporine treat- performed first for patients with systemic processes such ment showed significant increases in pathological find- as rheumatoid arthritis, Crohn disease, and multiple scle- ings such as glomerular sclerosis, tubular atrophy, and rosis rather than for isolated noninfectious uveitis. The interstitial fibrosis. However, a separate study in rheu- reasons are simple. The overall number of uveitis pa- matoid arthritis showed that of 22 patients who re- tients is dwarfed by the numbers of patients with rheu- ceived initial cyclosporine doses of less than 4 mg/kg per matoid arthritis and other systemic diseases. There is an day and subsequently received doses no higher than 5 even smaller number of patients with any particular di- mg/kg per day, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Noninfectious Uveitis

JAMA Ophthalmology , Volume 123 (5) – May 1, 2005

Loading next page...
 
/lp/american-medical-association/noninfectious-uveitis-V7DkhqLVyL
Publisher
American Medical Association
Copyright
Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.123.5.682
pmid
15883289
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL A Scarcity of Randomized Clinical Trials UTOIMMUNE DISEASES ARE MAKING THE years found a significant increase in serum creatinine lev- headlines these days, with the reporting els and a significant decrease in creatinine clearance and of results from clinical trial after clinical glomerular filtration rate. All renal effects were dose- trial of various new treatments. Not sur- dependent. Eleven of the patients who underwent renal A prisingly, such clinical trials have all been biopsy prior to and after 2 years of cyclosporine treat- performed first for patients with systemic processes such ment showed significant increases in pathological find- as rheumatoid arthritis, Crohn disease, and multiple scle- ings such as glomerular sclerosis, tubular atrophy, and rosis rather than for isolated noninfectious uveitis. The interstitial fibrosis. However, a separate study in rheu- reasons are simple. The overall number of uveitis pa- matoid arthritis showed that of 22 patients who re- tients is dwarfed by the numbers of patients with rheu- ceived initial cyclosporine doses of less than 4 mg/kg per matoid arthritis and other systemic diseases. There is an day and subsequently received doses no higher than 5 even smaller number of patients with any particular di- mg/kg per day,

Journal

JAMA OphthalmologyAmerican Medical Association

Published: May 1, 2005

References